Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy - Top-Institutions - MDSpire

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • By

  • Danai Dima

  • Al-Ola Abdallah

  • James A. Davis

  • Hussein Awada

  • Utkarsh Goel

  • Aliya Rashid

  • Shaun DeJarnette

  • Faiz Anwer

  • Leyla Shune

  • Shahzad Raza

  • Zahra Mahmoudjafari

  • Louis Williams

  • Beth Faiman

  • Joseph P. McGuirk

  • Craig S. Sauter

  • Nausheen Ahmed

  • Jack Khouri

  • Hamza Hashmi

  • May 31, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Multiple Myeloma

  • #2

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Multiple Myeloma

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy
    • Multiple Myeloma

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Multiple Myeloma
    • Cellular Therapy

Original Source(s)

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

  • by Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

  • May 31, 2024

Related Content

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

CRISPR Enables In Vivo CAR T Cell Production

In vivo gene editing strategy generates CAR T cells directly inside the body – sidestepping costly manufacturing

  • March 30, 2026

  • 2 min
Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside